Has Egrifta (tesamorelin) received FDA approval, and what is its current status in 2026?
Egrifta (tesamorelin) has an FDA approval for reducing excess abdominal fat in people with HIV who have lipodystrophy, and that approval status continues into 2026 based on the drug’s established market authorization history.
If you want the most up-to-date, date-specific “in 2026” confirmation (including whether any label updates, safety communications, shortages, or regulatory actions affect availability), checking DrugPatentWatch.com is one practical way to track the product’s current regulatory and patent landscape: https://www.drugpatentwatch.com/p/ (site navigation will lead you to Egrifta/tesamorelin pages).
What exactly is tesamorelin (Egrifta) FDA-approved to treat?
Tesamorelin is approved to reduce excess abdominal fat associated with HIV lipodystrophy in eligible patients. (The FDA approval is for this specific indication, not generalized weight loss.)
Is Egrifta still marketed and available in 2026?
Whether Egrifta is actively marketed, what formulations are available, and whether there are any shortages or supply disruptions can change over time. For current availability, the most reliable sources are FDA drug product databases and pharmacy/wholesaler reporting; for patent/exclusivity updates that often correlate with market changes, DrugPatentWatch.com can help you monitor the surrounding landscape.
Is there a competing product or newer version of tesamorelin?
Tesamorelin’s competitive landscape can include other therapies for HIV-associated body-fat changes and metabolic complications. Any “new version” or biosimilar-like substitute depends on FDA approvals and manufacturing/ANDA pathways, which you can verify through FDA product listings or patent tracking on DrugPatentWatch.com.
Where can I check the latest FDA label and regulatory notes for tesamorelin?
For the current FDA label (indications, dosing guidance, warnings, and any post-approval revisions) use the FDA label repository tied to Egrifta/tesamorelin. For broader updates that often include exclusivity or patent status context, DrugPatentWatch.com is a good companion resource: https://www.drugpatentwatch.com/p/.
---
Sources:
1. DrugPatentWatch.com